Chinese firm’s Sinovac COVID-19 vaccine, showed “remarkable” safety across all age groups, including the elderly, Vaccine Expert Panel (VEP) head Doktor Nina Gloriani said Tuesday.
Gloriani said the VEP’s recommendation to allow Sinovac inoculation on senior citizens was based on a review of data from Phase 1 and 2 clinical trials, publications, press releases from other countries, and the totality of evidence.
“We have seen the safety of Sinovac is remarkable across all age groups, including the elderly. Clinical trial findings showed that the Sinovac CoronaVac is well tolerated among older individuals,” she said in a press briefing.
Experts reevaluated the vaccine after several LGUs halted vaccination of senior citizens due to a shortage of AstraZeneca doses. Sinovac was initially recommended only for clinically healthy individuals aged 18 to 59.
“We are currently facing a worsening pandemic and we have very limited options… Right now, there are delays,” Gloriani said.
“The overall findings demonstrated that these vaccines induce neutralizing antibodies against SARS-CoV-2 and have good safety profiles both in the general population and the elderly,” she explained.